There is a renewed focus and commitment to finding innovative treatments for neurodegenerative diseases. For several decades and until recently, many factors, including too few disease-relevant biological hypotheses, the inherent complexity of the brain, and high patient heterogeneity have led to a graveyard of failed approaches over the last several decades and have produced few approved disease-modifying therapies. Recent technology advances over the last few years have reignited interest in this area and include improved understanding of the biology and disease pathology, in particular protein misfolding, new imaging approaches, predictive animal models, identification of new biomarkers and innovative target discovery technologies. Yumanity is one of the companies at the forefront of this emerging revolution.